Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3279814 | 0.76 | TAAR1 (0.74) | TDP1ALDH1A1RAB9ATAAR1NPC1 | |
| Hydrochloric Acid SCHEMBL29402155 | 0.75 | BCHE (0.64) | BCHEACHETDP1ALDH1A1RAB9A | |
| SCHEMBL10132006 | 0.74 | TAAR1 (0.63) | ALDH1A1RAB9ATAAR1NPC1GAA | |
| SCHEMBL11803291 | 0.73 | ACHE (0.68) | BCHEACHETDP1ALDH1A1RAB9A | |
| SCHEMBL4441852 | 0.72 | GAA (0.51) | TDP1ALDH1A1RAB9ATAAR1NPC1 | |
| SCHEMBL4446525 | 0.71 | TAAR1 (0.52) | ALDH1A1MAPK1RAB9ATAAR1NPC1 | |
| SCHEMBL12590098 | 0.71 | ACHE (0.69) | BCHEACHERAB9ATAAR1NPC1 | |
| SCHEMBL4961460 | 0.70 | NPC1 (0.61) | RAB9ATAAR1NPC1GAAFAAH | |
| SCHEMBL29339723 | 0.69 | KMT2A (0.70) | ALDH1A1RAB9ATAAR1NPC1MEN1 | |
| SCHEMBL4440938 | 0.69 | CES2 (0.74) | ALDH1A1RAB9ATAAR1NPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-3070081-A1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | Gilead Sciences, Inc. (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-02 | — | — | US | disclosed |
| EP-2788336-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2016-03-02 | — | — | EP | disclosed |
| US-9249128-B2 | Anti-cancer serine hydrolase inhibitory carbamates | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249128-B2 | Anti-cancer serine hydrolase inhibitory carbamates | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249128-B2 | Anti-cancer serine hydrolase inhibitory carbamates | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-02-02 | — | — | US | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-9096586-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| WO-2012058115-A2 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | CRAVATT BENJAMIN (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | BCHE 842/4885ACHE 849/4885TDP1 3466/4885 |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | BCHE 3020/4885ACHE 3621/4885TDP1 4331/4885 |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | BCHE 842/4885ACHE 849/4885TDP1 3466/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | BCHE 842/4885ACHE 849/4885TDP1 3466/4885 |
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | AADAC, DDAH1, PRSS1 | BCHE 252/4885ACHE 740/4885TDP1 2279/4885 |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | BCHE 3020/4885ACHE 3621/4885TDP1 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.